The White House has recognized six Cornell faculty members, three from the Ithaca campus and three from Weill Cornell Medicine, with 2025 Presidential Early Career Awards for Scientists and Engineers. The awards were announced Jan. 14.
A Cornell-led collaboration uncovered the equipment that enables bacteria to survive exposure to antibiotics: a shuttling mechanism that helps a complex of proteins pump out a wide spectrum of antibiotics from the cell.
The Class of 2025 learned on March 21 where they will be doing their internship and residency training – setting the stage for the next several years of their medical careers and lives.
Blood clots form in response to signals from the lungs of cancer patients – not from other organ sites, as previously thought – according to a preclinical study by Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center and University of California San Diego Health.
Many individuals seeking asylum in the United States show increased stress and pain symptoms that are associated with indications of cardiovascular disease, according to Weill Cornell Medicine researchers.
The new platform, which provided 100% protection from influenza and COVID-19 in mouse models, could vastly improve vaccine administration and the efficacy of the current flu vaccine.
A multicenter randomized, controlled clinical trial aims to test whether a minimally invasive treatment can relieve chronic pelvic pain and improve the quality of life for women with pelvic venous disease.
A group of immune proteins called the inflammasome can help prevent blood stem cells from becoming malignant by removing certain receptors from their surfaces and blocking cancer gene activity, according to a preclinical study by Weill Cornell Medicine investigators.
People with diabetes who were taking GLP-1 receptor agonist drugs had significantly lower rates of hospital readmission, wound reopening and hematoma after surgery, according to new study.
Weill Cornell Medicine has received a four-year, $1.4 million grant from the U.S. Department of Defense to investigate a new therapeutic approach for the most common form of kidney cancer.